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Abstract 
Objective 
Urinary hormonal markers may assist in increasing the efficacy of Fertility Awareness Based Methods 
(FABM). This study uses urinary pregnanediol-3a-glucuronide (PDG) testing to more accurately identify 
the infertile phase of the menstrual cycle in the setting of FABM. 
Methods 
Secondary analysis of an observational and simulation study, multicentre, European study. The study 
includes 107 women and tracks daily first morning urine (FMU), observed the changes in cervical 
mucus discharge, and ultrasonography to identify the day of ovulation over 326 menstrual cycles. The 
following three scenarios were tested: (A) use of the daily pregnandiol-3a-glucuronide (PDG) test alone; 
(B) use of the PDG test after the first positive urine luteinizing hormone (LH) kit result; (C) use of the 
PDG test after the disappearance of fertile type mucus. Two models were used: (1) one day of PDG 
positivity; or (2) waiting for three days of PDG positivity before declaring infertility. 
Results 
After the first positivity of a LH test or the end of fertile mucus, three consecutive days of PDG testing 
over a threshold of 5 μg/mL resulted in a 100% specificity for ovulation confirmation. They were 
respectively associated an identification of an average of 6.1 and 7.6 recognized infertile days. 
Conclusions 
The results demonstrate a clinical scenario with 100% specificity for ovulation confirmation and provide 
the theoretical background for a future development of a competitive lateral flow assay for the detection 
of PDG in the urine. 
Graphical abstract 
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1. Introduction 
Since the mid-20th century, urinary hormone assays have been proposed to help identify the fertile 
phase of the menstrual cycle [1], [2]. These assays can be used by women wishing to postpone 
pregnancy by using Fertility Awareness Based Methods (FABM). Three urinary hormonal testing 
methods have long been proposed in scientific literature to help identify the ovulatory period: oestrone-
3-glucuronide (E1G), pregnanediol-3a-glucuronide (PDG), and luteinizing hormone (LH) [3], [4]. In 
addition to urinary markers, cervical mucus is one of the most widely used biological markers for self-
estimating the beginning and end of the fertile phase in a menstrual cycle [5], [6], [7]. Furthermore, two 
clinical indicators of ovulation are broadly known, the mucus peak symptom [6], [8], [9], [10], [11] and the 
basal body temperature (BBT) rise. Instead of mucus or BBT as indicators, a hormonal marker of 
ovulation would be useful. Some home-based ovulation predictor kits based on LH identification in the 
urine have been marketed for this purpose [12], [13]. However, in a previous study, it was discovered that 
ovulation may sometimes be missed with LH kits if their threshold are above 20 mIU/mL [11]. 
Furthermore, there are many different amplitudes, configurations, and durations of the LH surge that 
might erroneously predict ovulation [14], [15]. 
A more direct and objective measure to confirm ovulation is the urinary measure of the metabolite of 
post ovulatory progesterone. Several authors have suggested that the use of single morning urinary 
samples of PDG above a threshold would be a better indicator of ovulation [16], [17], [18]. Even more, 
devices using this concept were at one time considered for marketing [19]. However, this approach was 
vulnerable to error due to the nature of the assays of urinary PDG and the variability in PDG 
concentration thought out the menstrual cycle [20]. Traditionally, PDG concentrations have been 
corrected for creatinine to avoid these problems; however, this correction adds a technical difficulty to 
develop simple-to-use, home-based-point of care devices. As a result, other methods combining 
electronic urinary monitors are being studied to address this problem [21], although they are likely to be 
cost prohibitive for many women. Despite the latter looking very promising, it is clear that other more 
affordable, easy to use, and versatile methods would be welcomed by FABM users. 
The combination of robust markers of ovulation, namely urinary hormones and cervical mucus, could 
synergistically improve the identification of the fertile and infertile phases. In the mid-nineteen nineties, 
researchers collected information from normally ovulating women regarding daily urinary hormone 
measures, recordings of basal body temperature, cervical mucus observations, and serial ovarian 
ultrasound in order to study the possibility for a PDG urine hormonal assay [11]. A database of 
information was created but due to legal-commercial disclosure agreements, the results regarding the 
role of PDG in confirming post-ovulatory infertility were not published until now; this paper will present 
these results. In this study we assessed the potential diagnostic qualities of these markers, focusing on 
a given urinary PDG concentration threshold to identify the post-ovulatory infertile phase of the cycle. 
2. Experimental 
2.1. Subjects 
This European prospective study was conducted between 1996 and 1997 in eight fertility centers: Aix-
en-Provence, Dijon, and Lyon (France), Milano and Verona (Italy), Düsseldorf (Germany), Liège 
(Belgium), and Madrid (Spain). It included healthy menstruating women aged 18–45 years with 
previous menstrual cycles of 24–34 days who had experience recording basal body temperature and 
monitoring cervical mucus. However, for the purpose of the current analysis, no women were excluded 
based on the duration of the cycle. 
Women with a history of infertility, pelvic inflammatory disease, cycle disturbances, disturbed follicular 
development, or current hormone therapy were excluded from the study. We also excluded women who 
had had gynaecological surgery, a delivery within the last three months, women who were 
breastfeeding, and competitive athletes. 
The study included 107 women and analyzed an average of three cycles per woman for a total of 326 
cycles. The original study that collected the data [11] was approved by the local ethics committee 
(Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Lyon). All 
participants gave their written informed consent. The study procedures were carried out in accordance 
with the Ethical Standards for Human Experimentation established by the Declaration of Helsinki. 
2.2. Methods 
2.2.1. Mucus symptoms 
Study participants checked for changes in cervical mucus two or three times daily, recording the 
sensation (dry, moist, wet, or slippery) and the consistency (tacky, creamy, or stretchy) of the mucus. 
This information allowed for the ability to distinguish between (i) days with no mucus felt or seen; (ii) 
days with mucus felt or seen but not having the characteristics of high fertility; and (iii) days with mucus 
that felt wet or slippery or that resembled an egg-white and had a stretchy appearance. The last day of 
clear, stretchy and/or lubricative mucus discharge was called the peak symptom [9], [22] 
2.2.2. Hormone assessments 
Assays were carried out on the first morning urine (FMU) with two 10–12 mL aliquots frozen on the day 
of collection at −20 °C in tubes containing gentamicin sulphate. On the day of analysis, the aliquots 
were thawed in a single laboratory and tested in duplicates for quantitative detection of oestrone-3-
glucuronide (E1G-ng/mL), pregnanediol-3a-glucuronide (PDG-μg/mL), follicle stimulating hormone 
(FSH-mIU/mL), and luteinizing hormone (LH-mIU/mL) using time-resolved fluorometric immunosorbent 
assays (Delfia). Each hormonal sample was repeated twice: the relative difference (i.e. CV) was 
respectively 5.96%, 10.79%, 8.66% and 7.17% for PDG, FSH, LH and E1G. We cannot provide 
detailed information on assay performance except the intra-assay CV’s. This data remains within the 
property of the funding company. 
2.2.3. Ultrasound scans 
The serial transvaginal ovarian ultrasounds (with follicle measurements) started either at the onset of 
the fertile cervical mucus or at the detection of the LH surge by the home test. These scans were 
carried out every other day until the largest follicle reached 16 mm, then every day until evidence of 
ovulation. To note that while there is increasing evidence to indicate that multiple ovarian follicular 
waves develop during the human menstrual cycle [22], the evidence always point towards the last wave 
being the ovulatory single event of a given cycle [23].The same physician at each centre performed the 
scans. The ultrasound-determined day of ovulation (US-DO) was the 24-h period that separated the 
sight of a mature follicle on one scan and either of the following on the second scan: (i) a change in the 
follicle size, shape, or sonographic density; (ii) follicle rupture; (iii) the presence of an early corpus 
luteum; (iv) the presence of free fluid in the cul-de-sac. If a woman missed an ultrasound examination, 
the US-DO was the first day after the last pre-ovulatory ultrasound with a follicle ⩾18 mm or the second 
day with a follicle <18 mm. 
2.3. Measured outcomes 
2.3.1. Fertility definitions 
The fertile phase was estimated during the pre-ovulatory phase as the period stretching from the first 
day of menses to the end of the US-DO. The infertile phase was defined as the day after ovulation day, 
up to the following menses. 
Positive PDG test was defined as a test result above a defined concentration threshold. A negative 
PDG test was defined as a test result below that threshold. Different PDG concentration thresholds in 
FMU samples were analyzed for specificity, sensitivity, true negative and true positive cycles. A cycle 
with at least one day with a positive PDG test in the fertile phase was classified as a false positive: i.e. 
PDG concentration was high despite being during the potentially fertile phase. A cycle with all days with 
negative PDG tests in the fertile phase was classified as a true negative: i.e. PDG was appropriately 
low during the potentially fertile phase. A cycle with days in the infertile phase with positive PDG tests 
was classified as a true positive: i.e. PDG was appropriately high during the infertile phase. A cycle 
without at least one day in the infertile phase with a positive PDG test was classified as a false 
negative: i.e. PDG was always low despite being in the infertile phase. 
The sensitivity was estimated as the proportion of true positives, that is, cycles with appropriate 
recognition of the post-ovulatory infertile phase. The specificity was estimated as the proportion of true 
negatives, that is, cycles with appropriate recognition of the pre-ovulatory fertile phase. Lack of 
specificity creates the risk of unplanned pregnancy, and therefore, a high specificity for ovulation 
confirmation was the main aim of the study. Achieving a specificity of 100% would mean that there is no 
positive test in the absence of ultrasound-confirmed ovulation, in other words, we would not want a 
woman to think she was infertile if she has not yet ovulated. 
2.3.2. Tested scenarios for different PDG thresholds 
The following scenarios were tested: (A) Use of the daily PDG test alone starting the first day of the 
cycle; (B) Use of the daily PDG test only after a first positive urine LH kit result (LH threshold of 
20 mIU/mL); and (C) Use of the PDG test only after the disappearance of highly fertile type mucus at 
the vulva, i.e. return to absence of mucus or mucus without the characteristics of high fertility. In the 
event of a second wave of highly fertile type mucus during the testing, the test was re-started following 
the disappearance of the second wave of highly fertile type mucus. The chosen LH threshold of 
20 mIU/mL was based on data from previous published analysis [15]. The two most common used 
thresholds of commercially available urinary LH kits are 20 and 25. The respective specificity and 
sensitivity were found to be 0.95 and 0.43 for a threshold of 20; and, 0.97 and 0.34 for 25. Given on 
these results, we chose 20 to be the best as it had the higher sensitivity. 
2.3.3. PDG test models and interpretation of the results 
We postulated two models of using the PDG test based on current FABM practices: (1) One day of 
positivity above a certain threshold is considered to be sufficient to declare infertility; or (2) Three 
consecutive days of positivity are observed before infertility is declared. 
2.4. Statistical analysis 
The best threshold was obtained through secondary analysis by performing a statistical analysis in a 
range from 0.5 to 15 μg/mL and determining the threshold based on specificity and sensitivity. 
Sensitivity and specificity were estimated with their 95% confidence intervals. Then a ROC (the 
Receiver Operating Characteristic) curve was used to describe the evolution of sensitivity and 
specificity according to the given threshold. A descriptive analysis of the cycle characteristics was 
performed using geometric mean, standard deviation, minimum, median, and maximum for quantitative 
data. Frequency was used for categorical variables. All statistical analyses were performed using the R 
software version 2.13.0 (The R Foundation for Statistical Computing). A p-value <0.05 was considered 
for statistical significance. 
3. Results 
Table 1 depicts the participants’ characteristics including hormonal profiling. The 107 subjects studied 
were 19–44 years old. Sixty-nine of them (64%) had at least one child before the study. The BMIs 
ranged between 17.1 and 28.3. Eleven women reported current smoking. The mean cycle length was 
28.1 days (range 22–44 days). The mean time to ovulation was 14.8 days (range 9–33 days) and the 
mean post-ovulatory phase length was 13.3 days (range 7–17 days). In 28 cycles out of the 326 
monitored, the first ultrasound was performed after ovulation and, in 15 others, it was not possible to 
determine exactly the day of ovulation by ultrasound. This left 283 ovulatory cycles for analysis. In a 
sub-analysis, out of the 206 available cycles with complete records on mucus coding, eight cycles (4%) 
showed two waves of fertile-type cervical mucus separated by a vaginal dry phase. Ovulation followed 
the last wave. It is well recognized that this is a product of variations in hormonal patterns within the 
menstrual cycle [24]. In addition, as previously published [32], no differences were observed between 
different BMI groups and PDG mean levels: 12.41(0.56), 13.09 (0.53), 11.70 (0.80) μg/mL for BMI 
ranges of <19.2, 19.2–23.4, and >23.4 respectively. 
Table 1. Women and cycles characteristics. 
Characteristics Mean (±sem) Minimum Maximum 
Women 
Age (years) 32.42 (0.35) 19 44 
Age at Menarche (years) 13.17 (0.1) 9 17 
Body mass index (kg/m2) 21.27 (0.15) 17.12 28.34 
Sport activity (h/week) 1.16 (0.13) 0 9 
Regular smokers (%) 11   
Vegans (%) 4    
Cycles 
Cycle length (days) 28.07 (0.17) 22 44 
Follicular phase (days) 14.76 (0.17) 9 33 
Luteal phase (days) 13.35 (0.1) 7 17  
FSH (mIU/mL) 
Early follicular phase 3.61 (0.19) 0.06 26.26 
Periovulatory phase 5.24 (0.26) 0.08 21.42 
Luteal phase 1.73 (0.1) 0.06 10.75  
LH (mIU/mL) 
Early follicular phase 3.56 (0.13) 0.08 11.77 
Periovulatory phase 15.5 (0.66) 0.54 51.82 
Luteal phase 6.19 (0.37) 0.08 52.99  
E1–3-G (ng/mL) 
Early follicular phase 10.61 (0.34) 1.17 45.44 
Periovulatory phase 50.76 (1.87) 4.44 281.18 
Characteristics Mean (±sem) Minimum Maximum 
Luteal phase 29.72 (1.21) 2.39 213.52  
Pd-3α-G (μg/mL) 
Early follicular phase 2.34 (0.09) 0.18 19.62 
Periovulatory phase 3.02 (0.1) 0.31 14.68 
Luteal phase 12.66 (0.37) 1.53 64.84 
Average hormonal concentrations were estimated at the three phases of the cycle: at days 2, 3, and 4 of the cycle 
for the early follicular phase, at US-DO ± 1 for the periovulatory phase, and at US-DO +5,+7, and +9 for the luteal 
phase. 
The specificity and sensitivity of the PDG test in a range from 0.5 to 15 μg/mL with all various proposed 
scenarios is depicted in the Receiver Operating Characteristic curves in Fig. 1. The main goal of this 
study was to achieve a low false positive rate, that is, highest specificity, to ensure the lowest simulated 
pregnancy rate and to confirm ovulation. The ideal concentration threshold in a FMU sample for PDG 
positivity was found to be at 5 μg/mL. 
 
Fig. 1. ROC curves presenting the evolution of true and false positive rates according to the chosen 
threshold of PDG tests; one ROC curve per scenario. 
The two scenarios with the highest specificity are Scenario B; using the PDG test for three consecutive 
days after a first positive urine LH kit result and Scenario C which is the most specific; using the PDG 
test for three consecutive days after high fertility cervical mucus is detected. 
Table 2, Table 3 show the number of daily PDG tests used for each of the three scenarios, the number 
of recognized true infertile days by the testing, the test’s specificity and sensitivity. 
Table 2. Estimated measures of the performance of PDG positivity in the one-day model 
(threshold: 5 μg/mL). 
Testing scenarios 
Number of daily testing 
One positive PDG result 
Number of 
days tested 
Number of 
recognized true 
infertile days 
Sensitivity 
% 
Specificity 
% 
(A) Daily PDG testing alone from day 1 12.1 5.5 0.986 0.534 
(B) PDG daily testing only after a 
positive LH test 2.3 6.5 0.756 0.776 
(C) PDG testing following peak fertility 
(i.e. presence of high fertile type mucus 
at the vulva followed by a change to 
non-fertile type) 
2.8 9.5 0.984 0.907 
Table 3. Estimated measures of the performance of PDG positivity in the 3-day model 
(threshold: 5 μg/mL). 
Testing scenarios 
Number of daily testing 
Three daily consecutive positive PDG results 
Number of 
days tested 
Number of 
recognized true 
infertile days 
Sensitivity 
% 
Specificity 
% 
(A) Daily PDG testing alone from day 1 18.6 6.6 0.929 0.862 
(B) PDG daily testing only after a positive 
LH test 5.2 6.1 0.721 0.986 
(C) PDG testing following peak fertility (i.e. 
presence of high fertile type mucus at the 
vulva followed by a change to non-fertile 
type) 
5.9 7.6 0.922 1 
Table 2 shows the results associated with scenarios using the one-day model of positive PDG testing 
above a specific threshold. Table 3 refers to the three-day model (three days of consecutive positive 
tests). The three scenarios were applied to both models. 
The most specific scenario, which combined the use of three positive PDG tests after the identification 
of high fertility mucus (Scenario C), resulted in 92% of sensitivity for ovulation. In this scenario, 6 days 
were tested per cycle and 7.6 days are recognized as infertile during the post-ovulatory phase. If we 
ignore the 8% of cycles with lack of sensitivity, 8.1 days are recognized as infertile during the post-
ovulatory phase. 
The other scenarios were all limited in some way. First, when using LH positivity as the starting point for 
the PDG test (Scenario B), there was limited sensitivity with only 76% of the cycles achieving a positive 
LH test and thus precluding the use the PDG test. Second, when using the PDG test alone (Scenario 
A), there was limited specificity and the PDG test occasionally read positive before ovulation had taken 
place. 
In a sub-analysis to take into account sport activity, data was available for 76 women. We did it to 
assess whether sport activity may be associated with a reduced luteal PDG. First, we divided 
participants in three groups: no sport-activity, intensive sport-activity for less than 3 h per week and for 
more than 3 h per week. The sport activity was assessed only once per woman and we analyzed the 
data accordingly. Within each group, PDG values from three days of each cycle were averaged to 
obtain one value per cycle (i.e. the mean PDG level of days US-DO +5, +7, and +9). We then averaged 
all these mean PDG levels for all the cycles within a given group. In this analysis, the results obtained 
were 11.23, 12.01 and 11.14 for the three groups respectively (p = 0.77, i.e. the difference was not 
statistically significant). 
4. Discussion 
The present study predicts that the use of three consecutive days of PDG testing over a threshold of 
5 μg/mL in a FMU sample will result in a perfect specificity for ovulation confirmation following fertility-
type mucus identification. The 100% confirmation would allow women to identify the absolute infertile 
period after ovulation for the sake of avoiding pregnancy. On the other hand, the rationale behind the 
fact that the combination of LH/PDG did not give a perfect specificity can be found on recent LH 
research [15]. It is now known that LH levels present some variability in amplitude, duration and 
configuration with ovulation sometimes occurring later than one day after the LH surge. It is then 
possible that our proposed PDG test protocol may give a false negative since it may test too early to 
show a PDG surge. However, we believe the high specificity obtained is still within the clinically relevant 
range (Sp = 0.986). 
The beginning of the fertile phase still requires the use of a first indicator; either, a count of days from 
the onset of the cycle, or the presence of mucus, felt or seen, at the vulva [6] or the detection of a 
significant rise in urinary E1G, either alone or in various combinations [25], [26], [27]. To identify the end of 
the fertile phase, our results confirm the interest of using either a LH test first or to rely on days 
following the presence of cervical mucus for FABM users, and then confirm the infertility using three 
consecutive days of PDG testing over a threshold of 5 μg/mL in a FMU sample. A noon sample of 
urinary LH above a set threshold has been considered sufficient to identify the imminence of ovulation 
[28]. Alternatively, instead of relying on the same threshold for every woman, electronic devices have 
been developed to identify a significant increase over a given woman’s baseline hormonal levels during 
the previous days [29]. Our results show that three consecutive days of PDG positivity above a specific 
threshold following LH positivity or the end of fertile-type cervical mucus will confirm infertility with a 
high predictive specificity. 
Clinical an-ovulatory scenarios such as pre-menopause and polycystic ovarian disease (PCOD), has 
been mentioned as challenges for FABM use. Firstly, the effect of these scenarios should be negligible 
in the interpretation of the PDG method; since, it is only with those ovulatory cycles that the rise of 
urinary PDG occurs. However, it is been long reported that there are clinical scenarios when luteal 
progesterone levels, and consequently PDG levels as well, may be found at lower level than normal: in 
women with unexplained infertility, after ovulation induction with clomiphene citrate or gonadotropins, in 
women with hyperprolactinemia, recurrent miscarriages, luteinizing unruptured follicles, in 
oligomenorrheic obese women with or without hirsutism such as PCOD, and in perimenopausal women 
[30], [31], [32]. Our current proposed protocol lacks the power to discriminate for all these conditions 
because it is based on one single threshold, yet, it could be the source of future research on the 
relationship between cervical mucus, LH and PDG surges. Secondly and even more importantly, it is 
the combination of two markers (cervical mucus or LH) plus PDG that may provide the safety net 
needed in these conditions with reduced PDG level. For instance, it is recognized that use of cervical 
mucus monitoring in FABM can help to identify approaching ovulation even in pre-menopause [24]. 
Thirdly, in clinical situations such as vaginal infections when the cervical mucus essentially becomes 
non-interpretable, the use of urinary LH testing could be used as substitute as mentioned in our 
protocols. Finally, despite the fact that the clinical question of accurately identifying the infertile phase of 
the menstrual cycle is an old one (1, 2, and 20), the proposed model is new. No quantitative 
assessment of the use of PDG as adjunct to the concurrent use of FABM has ever been published, nor 
a study has used such a large dataset. 
With these results, the next major challenge will be the development of a simple competitive lateral flow 
assay for the detection of PDG in the urine. The ability to develop such assays has been available for 
several years and the manufacturing processes of these tests are well known. Similar urinary tests 
such as those used to identify commonly abused substances could be adapted for this purpose given 
that PDG and these substances have comparable molecular weights [33]. 
One further theoretical limitation of our study is that the algorithms used were based on multiple cycles 
per participants, leading to potentially to overestimates of specificity and sensitivity. To quantify for this 
effect, a mixed regression model for repeated measurement was used to describe the PDG level during 
the luteal phase (at US-DO +5, +7, and +9). The inter-women and intra-women coefficients of variation 
were respectively 30% and 11%. However, we did not use a validation dataset to confirm the sensitivity 
and specificity: our estimates of performance can be overly optimistic. It would be wise to confirm these 
results using other datasets in future research. This fact might indeed contribute to an overestimate of 
specificity, but not necessarily invalidate the results in a clinical setting. Likewise, the fact that our PDG 
assays were tested only among European women, it may potentially limits the study’s results yet not 
necessarily invalidating our findings [34]. A clinical study based on the proposed PDG devices would 
again need to address concerns such a different population and racial differences. 
Given that this test has a dual purpose (to confirm the end of the fertile period for women wishing to get 
pregnant and identifying the infertile phase for those wishing to avoid pregnancy) it is very versatile. 
The 100% specificity for ovulation in these scenarios would be helpful to identify those women with 
adequate ovulation for the purpose of an infertility work-up, providing a home-based alternative for 
serum progesterone testing. For those wishing to postpone pregnancy, the high specificity for ovulation 
demonstrated here provides a simple and very reliable identification for the post-ovulatory infertile 
phase. In order to make this approach practical, the cost of the simple PDG test ought to remain low. 
Future studies could assess the two best scenarios (B and C) for women who are seeking to avoid and 
achieve pregnancy. 
On a side note, it was noted that in 2% of the cycles (6/283), menses occurred beyond the generally 
accepted 16 days post-ovulation, in these few cycles, we question whether the ultrasound 
determination of the day of ovulation was off by one day or two or an early pregnancy loss occurred. 
Our assessment of these rare events led us to conclude that the potential bias would not be significant. 
In order to provide women with a simple, home-based test to identify the absolute infertile period after 
ovulation, we have demonstrated a new objective measure that is 99–100% specific for the ovulation 
event as confirmed by ultrasound. In order to avoid the previous challenge of the individual woman’s 
menstrual cyclic variations in urinary concentrations of PDG, we have proposed a novel model that 
employs three consecutive days of PDG tests above a threshold of 5 μg/mL after either LH positivity or 
highly fertile mucus. This model is 99–100% specific for ovulation depending of the scenario used and 
is thus a very promising tool for women wanting a conservative and reliable measure to complement 
their Fertility Awareness Based Method. 
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